AZN FDA calendar & decision history AstraZeneca/Alexion · 1 upcoming · 16 past FDA decisions
Upcoming FDA catalysts AZN · Dec 31, 2026 Ultomiris (ravulizumab) — IgA nephropathy (I CAN, sBLA) FDA decision history (16) Jun 12, 2026✓ Approved TRUQAP (capivasertib) in combi May 28, 2026✓ Approved Imfinzi (durvalumab) May 22, 2026✓ Approved Datopotamab Deruxtecan (Dato-D May 18, 2026✓ Approved BAXFENDY (baxdrostat) May 15, 2026✓ Approved ENHERTU (trastuzumab deruxteca Apr 28, 2026✓ Approved BREZTRI AEROSPHERE (budesonide Apr 27, 2026✓ Approved SAPHNELO (anifrolumab-fnia) Feb 20, 2026✓ Approved FDA decision Dec 15, 2025✓ Approved FDA decision Nov 25, 2025✓ Approved FDA decision Nov 20, 2025✓ Approved FDA decision Oct 17, 2025✓ Approved FDA decision Jun 23, 2025✓ Approved FDA decision Mar 31, 2025✓ Approved FDA decision Jan 27, 2025✓ Approved FDA decision Jan 17, 2025✓ Approved FDA decision See the full 2026 PDUFA calendar → This page aggregates AZN's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio